September 12, 2007
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
Key Points
Key points are not available for this paper at this time.
Abstract
The outcome of treatment of AL amyloidosis with high-dose melphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalan plus dexamethasone. (ClinicalTrials.gov number, NCT00344526 ClinicalTrials.gov.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
A
Arnaud Jaccard
Centre Hospitalier Universitaire de Limoges
Philippe Moreau
Hôtel-Dieu de Paris
V
Véronique Leblond
Sorbonne Université
Journals
New England Journal of Medicine
Actions
Institutions
Centre National de la Recherche Scientifique
Inserm
Université Paris Cité
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...